Breast Cancer Clinical Trials in Nashville

Showing 181-200 of 605 trials

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT04434040

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

Breast CancerTriple Negative Breast CancerResidual Cancer+1 more

Dana-Farber Cancer Institute40 participantsStarted Jul 2020

San Francisco, California, United States • Chicago, Illinois, United States • New Lenox, Illinois, United States +4 more locations

Active Not RecruitingPhase 1< 1 mile

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.

Solid TumorsTriple Negative Breast Cancer (TNBC)Urothelial Cancer+1 more

Adcentrx Therapeutics144 participantsStarted Sep 2023

Los Angeles, California, United States • Los Angeles, California, United States • St. Petersburg, Florida, United States +18 more locations

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

A Study of ADRX-0706 in Select Advanced Solid Tumors

Breast Cancer Trials in Other Cities

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

MGC018 With or Without MGA012 in Advanced Solid Tumors

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

Proton Radiation for Stage II/III Breast Cancer

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

MarginProbe 2.0 Data Collection Protocol

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Other Conditions in Nashville